Recurrent Risk of Adverse Pregnancy Outcome

Obstetrics and Gynecology Clinics of North America

Volumn 35, Issue 3, 2008, Pages 459-471

  Moore, Lisa E ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA FETOPROTEIN; ALPHA TOCOPHEROL; ANTIHYPERTENSIVE AGENT; ASCORBIC ACID; CHORIONIC GONADOTROPIN; CORTICOSTEROID; HEPARIN; HYDROXYPROGESTERONE; METFORMIN; PLACEBO; PROGESTERONE;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DIABETIC DIET; DISEASE COURSE; DRUG EFFECT; FETUS DEATH; HELLP SYNDROME; HUMAN; LOW DRUG DOSE; MATERNAL HYPERTENSION; MATERNAL MORBIDITY; MATERNAL MORTALITY; NEWBORN MORBIDITY; NEWBORN MORTALITY; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL CARE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; STILLBIRTH; TRANSVAGINAL ECHOGRAPHY; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION;

DIABETES, GESTATIONAL; FEMALE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PREMATURE BIRTH; RECURRENCE; RISK FACTORS; STILLBIRTH;

EID: 49949087432     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ogc.2008.04.003     Document Type: Review

References (58)

1. Aucott S.W., Williams T.G., Hertz R.H., et al. Rigorous management of insulin-dependent diabetes mellitus during pregnancy. Acta Diabetol 31 3 (1994) 126-129
2. Bottalico J.N. Recurrent gestational diabetes: risk factors, diagnosis, management, and implications. Semin Perinatol 31 3 (2007) 176-184
3. Groop L.C. Pathogenesis of insulin resistance in type 2 diabetes: a collision between thrifty genes and an affluent environment. Drugs 58 Suppl 1 (1999) 11-12 [discussion: 75-82]
4. Groop L.C. Insulin resistance: the fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1 Suppl 1 (1999) S1-S7
5. MacNeill S., Dodds L., Hamilton D.C., et al. Rates and risk factors for recurrence of gestational diabetes. Diabetes Care 24 4 (2001) 659-662
6. Major C.A., deVeciana M., Weeks J., et al. Recurrence of gestational diabetes: who is at risk?. Am J Obstet Gynecol 179 4 (1998) 1038-1042
7. Glueck C.J., Wang P., Kobayashi S., et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 77 3 (2002) 520-525
8. Glueck C.J., Goldenberg N., Wang P., et al. Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum Reprod 19 3 (2004) 510-521
9. Tuomilehto J., Lindstrom J., Eriksson J.G., et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 18 (2001) 1343-1350
10. Dempsey J.C., Sorensen T.K., Williams M.A., et al. Prospective study of gestational diabetes mellitus risk in relation to maternal recreational physical activity before and during pregnancy. Am J Epidemiol 159 7 (2004) 663-670
11. Oken E., Ning Y., Rifas-Shiman S.L., et al. Associations of physical activity and inactivity before and during pregnancy with glucose tolerance. Obstet Gynecol 108 5 (2006) 1200-1207
12. Spong C.Y. Prediction and prevention of recurrent spontaneous preterm birth. Obstet Gynecol 110 2 Pt 1 (2007) 405-415
13. da Fonseca E.B., Bittar R.E., Carvalho M.H., et al. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 188 2 (2003) 419-424
14. Ambrose S., Rhea D.J., Istwan N.B., et al. Clinical and economic outcomes of preterm labor management: inpatient vs outpatient. J Perinatol 24 8 (2004) 515-519
15. Yost N.P., Owen J., Berghella V., et al. Second-trimester cervical sonography: features other than cervical length to predict spontaneous preterm birth. Obstet Gynecol 103 3 (2004) 457-462
16. Goldenberg R.L., Andrews W.W., Faye-Petersen O., et al. The Alabama preterm birth project: placental histology in recurrent spontaneous and indicated preterm birth. Am J Obstet Gynecol 195 3 (2006) 792-796
17. Iams J.D., Goldenberg R.L., Mercer B.M., et al. The Preterm Prediction Study: recurrence risk of spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 178 5 (1998) 1035-1040
18. Owen J., Yost N., Berghella V., et al. Can shortened midtrimester cervical length predict very early spontaneous preterm birth?. Am J Obstet Gynecol 191 1 (2004) 298-303
19. Hibbard J.U., Tart M., and Moawad A.H. Cervical length at 16-22 weeks' gestation and risk for preterm delivery. Obstet Gynecol 96 6 (2000) 972-978
20. Meis P.J., Klebanoff M., Thom E., et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 348 24 (2003) 2379-2385
21. O'Brien J.M., Adair C.D., Lewis D.F., et al. Progesterone vaginal gel for the reduction of recurrent preterm birth: primary results from a randomized, double-blind, placebo-controlled trial. Ultrasound Obstet Gynecol 30 5 (2007) 687-696
22. Rouse D.J., Caritis S.N., Peaceman A.M., et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med 357 5 (2007) 454-461
23. Fonseca E.B., Celik E., Parra M., et al. Progesterone and the risk of preterm birth among women with a short cervix. N Engl J Med 357 5 (2007) 462-469
24. Andrews W.W., Copper R., Hauth J.C., et al. Second-trimester cervical ultrasound: associations with increased risk for recurrent early spontaneous delivery. Obstet Gynecol 95 2 (2000) 222-226
25. Colombo D.F. Predicting spontaneous preterm birth. BMJ 325 7359 (2002) 289-290
26. Durnwald C.P., Walker H., Lundy J.C., et al. Rates of recurrent preterm birth by obstetrical history and cervical length. Am J Obstet Gynecol 193 3 Pt 2 (2005) 1170-1174
27. Sanchez-Ramos L., Kaunitz A.M., and Delke I. Progestational agents to prevent preterm birth: a meta-analysis of randomized controlled trials. Obstet Gynecol 105 2 (2005) 273-279
28. Meis P.J., Klebanoff M., Dombrowski M.P., et al. Does progesterone treatment influence risk factors for recurrent preterm delivery?. Obstet Gynecol 106 3 (2005) 557-561
29. ACOG Committee Opinion No. 291: use of progesterone to reduce preterm birth. Obstet Gynecol 102 (2003) 1115-1116
30. Yost N.P., Owen J., Berghella V., et al. Effect of coitus on recurrent preterm birth. Obstet Gynecol 107 4 (2006) 793-797
31. Eller A.G., Branch D.W., and Byrne J.L. Stillbirth at term. Obstet Gynecol 108 2 (2006) 442-447
32. Silver R.M. Fetal death. Obstet Gynecol 109 1 (2007) 153-167
33. Fretts R.C. Etiology and prevention of stillbirth. Am J Obstet Gynecol 193 6 (2005) 1923-1935
34. Froen J.F., Arnestad M., Frey K., et al. Risk factors for sudden intrauterine unexplained death: epidemiologic characteristics of singleton cases in Oslo, Norway, 1986-1995. Am J Obstet Gynecol 184 4 (2001) 694-702
35. Huang D.Y., Usher R.H., Kramer M.S., et al. Determinants of unexplained antepartum fetal deaths. Obstet Gynecol 95 2 (2000) 215-221
36. Smith G.C., Yu C.K., Papageorghiou A.T., et al. Maternal uterine artery Doppler flow velocimetry and the risk of stillbirth. Obstet Gynecol 109 1 (2007) 144-151
37. Rey E., Kahn S.R., David M., et al. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 361 9361 (2003) 901-908
38. Oshiro B.T., Silver R.M., Scott J.R., et al. Antiphospholipid antibodies and fetal death. Obstet Gynecol 87 4 (1996) 489-493
39. Reddy U.M. Prediction and prevention of recurrent stillbirth. Obstet Gynecol 110 5 (2007) 1151-1164
40. Rayburn W.F., and McKean H.E. Maternal perception of fetal movement and perinatal outcome. Obstet Gynecol 56 2 (1980) 161-164
41. Leader L.R., Baillie P., and Van Schalkwyk D.J. Fetal movements and fetal outcome: a prospective study. Obstet Gynecol 57 4 (1981) 431-436
42. Frias Jr. A.E., Luikenaar R.A., Sullivan A.E., et al. Poor obstetric outcome in subsequent pregnancies in women with prior fetal death. Obstet Gynecol 104 3 (2004) 521-526
43. Hjartardottir S., Leifsson B.G., Geirsson R.T., et al. Recurrence of hypertensive disorder in second pregnancy. Am J Obstet Gynecol 194 4 (2006) 916-920
44. Pridjian G., and Puschett J.B. Preeclampsia. Part 1: clinical and pathophysiologic considerations. Obstet Gynecol Surv 57 9 (2002) 598-618
45. van Rijn B.B., Hoeks L.B., Bots M.L., et al. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol 195 3 (2006) 723-728
46. Branch D.W., Porter T.F., Rittenhouse L., et al. Antiphospholipid antibodies in women at risk for preeclampsia. Am J Obstet Gynecol 184 5 (2001) 825-832 [discussion: 832-4]
47. Sibai B.M. Diagnosis, prevention, and management of eclampsia. Obstet Gynecol 105 2 (2005) 402-410
48. Qiu C., Williams M.A., Leisenring W.M., et al. Family history of hypertension and type 2 diabetes in relation to preeclampsia risk. Hypertension 41 3 (2003) 408-413
49. Hnat M.D., Sibai B.M., Caritis S., et al. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol 186 3 (2002) 422-426
50. Mostello D., Catlin T.K., Roman L., et al. Preeclampsia in the parous woman: who is at risk?. Am J Obstet Gynecol 187 2 (2002) 425-429
51. Mostello D., Kallogjeri D., Tungsiripat R., et al. Recurrence of preeclampsia: effects of gestational age at delivery of the first pregnancy, body mass index, paternity, and interval between births. Am J Obstet Gynecol (Feb 14, 2008) [Epub ahead of print]
52. Chames M.C., Haddad B., Barton J.R., et al. Subsequent pregnancy outcome in women with a history of HELLP syndrome at < or = 28 weeks of gestation. Am J Obstet Gynecol 188 6 (2003) 1504-1507 [discussion: 1507-08]
53. Conde-Agudelo A., Villar J., and Lindheimer M. World Health Organization systematic review of screening tests for preeclampsia. Obstet Gynecol 104 6 (2004) 1367-1391
54. Spinnato II J.A., Freire S., Pinto E., et al. Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. Obstet Gynecol 110 6 (2007) 1311-1318
55. Sibai B.M. Prevention of preeclampsia: a big disappointment. Am J Obstet Gynecol 179 5 (1998) 1275-1278
56. Sibai B.M., Caritis S.N., Thom E., et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 329 17 (1993) 1213-1218
57. Heyborne K.D. Preeclampsia prevention: lessons from the low-dose aspirin therapy trials. Am J Obstet Gynecol 183 3 (2000) 523-528
58. Duhl A.J., Paidas M.J., Ural S.H., et al. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 197 5 (2007) 457 e1-e21